EP4463169A1 — Compositions comprising a chemokine receptor pathway inhibitor
Assigned to Dimerix Bioscience Pty Ltd · Expires 2024-11-20 · 1y expired
What this patent protects
A composition comprising: i. at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof, in particular repagermanium or propagermanium; ii. a diluent in a concentration from 30 to 70 % w/w; iii. a binder in a concentration from 2 to 5…
USPTO Abstract
A composition comprising: i. at least one chemokine receptor 2 (CCR2) pathway inhibitor or a pharmaceutically acceptable salt thereof, in particular repagermanium or propagermanium; ii. a diluent in a concentration from 30 to 70 % w/w; iii. a binder in a concentration from 2 to 5 % w/w; iv. a disintegrant in a concentration from 2 to 8% w/w; and v. a lubricant in a concentration from 0.05 to 5% w/w; and methods of treatment with same.
Drugs covered by this patent
- Pulmicort Respules (BUDESONIDE) · AstraZeneca K.K.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.